Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C53H88N4O51S8 |
| Molecular Weight | 1853.782 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 28 / 28 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](OC)[C@H](OC)[C@H]5NC(=O)CCCCCNC(=O)CCCC[C@@H]6SC[C@@H]7NC(=O)N[C@H]67)[C@H](OC)[C@H]4OC)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3OS(O)(=O)=O)[C@H](OC)[C@H]2OC)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O
InChI
InChIKey=MUQWDYYIYNYBQD-OFHININYSA-N
InChI=1S/C53H88N4O51S8/c1-86-30-22(17-93-110(65,66)67)96-48(29(33(30)87-2)56-27(59)15-9-8-12-16-54-26(58)14-11-10-13-25-28-21(20-109-25)55-53(64)57-28)101-36-34(88-3)42(90-5)50(103-40(36)46(60)61)100-32-24(19-95-112(71,72)73)98-52(45(108-116(83,84)85)39(32)106-114(77,78)79)102-37-35(89-4)43(91-6)51(104-41(37)47(62)63)99-31-23(18-94-111(68,69)70)97-49(92-7)44(107-115(80,81)82)38(31)105-113(74,75)76/h21-25,28-45,48-52H,8-20H2,1-7H3,(H,54,58)(H,56,59)(H,60,61)(H,62,63)(H2,55,57,64)(H,65,66,67)(H,68,69,70)(H,71,72,73)(H,74,75,76)(H,77,78,79)(H,80,81,82)(H,83,84,85)/t21-,22+,23+,24+,25-,28-,29+,30+,31+,32+,33+,34-,35-,36-,37-,38-,39-,40-,41+,42+,43+,44+,45+,48+,49-,50+,51+,52+/m0/s1
Idrabiotaparinux, a biotinylated idraparinux, was developed by Sanofi as a long-acting inhibitor of factor Xa. Idrabiotaparinux participated in clinical trials phase III to prevent stroke and systemic thromboembolic events in patients with atrial fibrillation. The study was prematurely terminated, because of unknown reason. In addition, the drug was involved in phase II for patients with pulmonary embolism. Sanofi has discontinued development of idrabiotaparinux.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Idrabiotaparinux treatment for venous thromboembolism. | 2012-01-14 |
|
| Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis. | 2011-01 |
|
| Development of idraparinux and idrabiotaparinux for anticoagulant therapy. | 2009-11 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000175130
Created by
admin on Mon Mar 31 23:05:17 GMT 2025 , Edited by admin on Mon Mar 31 23:05:17 GMT 2025
|
PRIMARY | |||
|
774531-07-6
Created by
admin on Mon Mar 31 23:05:17 GMT 2025 , Edited by admin on Mon Mar 31 23:05:17 GMT 2025
|
PRIMARY | |||
|
H44R6RJT3S
Created by
admin on Mon Mar 31 23:05:17 GMT 2025 , Edited by admin on Mon Mar 31 23:05:17 GMT 2025
|
PRIMARY | |||
|
16202213
Created by
admin on Mon Mar 31 23:05:17 GMT 2025 , Edited by admin on Mon Mar 31 23:05:17 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
